Bayer Pharma has six „blockbuster candidates“ at the start
Stefan Oelrich, Member of Bayer's Board of Management and Head of the Pharmaceuticals Division, is confident about the development pipeline. As one important patent expires, he points to a range of new products that will generate big sales.
mehrInterview withStefan Oelrich
von Annette Becker
